{
    "eid": "2-s2.0-84994338421",
    "title": "Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: Findings from the ACCORD clinical trial",
    "cover-date": "2016-11-01",
    "subject-areas": [
        {
            "$": "Advanced and Specialized Nursing",
            "@code": "2902"
        },
        {
            "$": "Endocrinology",
            "@code": "2712"
        },
        {
            "$": "Internal Medicine",
            "@code": "2724"
        }
    ],
    "keywords": [],
    "authors": [
        "Hetal S. Shah"
    ],
    "citedby-count": 40,
    "ref-count": 34,
    "ref-list": [
        "Heart Disease and Stroke Statistics - 2014 Update: A report from the American Heart Association",
        "8. Cardiovascular disease and risk management",
        "Global Status Report on Non-Communicable Diseases 2014",
        "Intensive glucose control and macrovascular outcomes in type 2 diabetes",
        "Effects of intensive glucose lowering in type 2 diabetes",
        "Long-term effects of intensive glucose lowering on cardiovascular outcomes",
        "Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial",
        "The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study",
        "The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study",
        "Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial",
        "The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial",
        "Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods",
        "Genetic Variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes",
        "Basal insulin and cardiovascular and other outcomes in dysglycemia",
        "Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage",
        "Genotype imputation with thousands of genomes",
        "METAL: Fast and efficient meta-analysis of genomewide association scans",
        "Calculating the number needed to treat for trials where the outcome is time to an event",
        "The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans",
        "Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus",
        "Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: What we know and what we need to know",
        null,
        "Association between Estrogen Receptor \u03b1 Gene Variation and Cardiovascular Disease",
        "Post-Genomic update on a classical candidate gene for coronary artery disease: ESR1",
        "Annotation of functional variation in personal genomes using RegulomeDB",
        "Diabetes-related Changes in cAMP Response Element-binding Protein Content Enhance Smooth Muscle Cell Proliferation and Migration",
        "Elevated levels of renal and circulating Nop-7-associated 2 (NSA2) in rat and mouse models of diabetes, in mesangial cells in vitro and in patients with diabetic nephropathy",
        "Nop-7-Associated 2 (NSA2), a candidate gene for diabetic nephropathy, is involved in the TGF\u03b21 pathway",
        "Genome regulation by long noncoding RNAs",
        "The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression",
        "Noncoding RNAs in diabetes vascular complications",
        "Noncoding RNAs in vascular disease",
        "Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL- associated serine proteases 1 and 2, and the MBL-associated protein MAp19",
        "BMC Proc"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chapel Hill",
            "affilname": "UNC Eshelman School of Pharmacy",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Charlottesville",
            "affilname": "University of Virginia School of Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Krakow",
            "affilname": "Jagiellonian University Medical College",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Chapel Hill",
            "affilname": "UNC School of Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Seattle",
            "affilname": "University of Washington",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Hamilton",
            "affilname": "Hamilton Health Sciences",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Raleigh",
            "affilname": "NC State University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Joslin Diabetes Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Harvard Medical School",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Calgary",
            "affilname": "Cumming School of Medicine",
            "affiliation-country": "Canada"
        }
    ],
    "funding": [
        "Alberta Innovates-Health Solutionswith a Health",
        "National Institutes of Health",
        "National Institutes of Health",
        "National Heart, Lung, and Blood Institute",
        "National Heart, Lung, and Blood Institute",
        "National Center for Advancing Translational Sciences",
        "National Center for Advancing Translational Sciences",
        "Joslin Diabetes Center",
        "Juvenile Diabetes Research Foundation United States of America",
        "Juvenile Diabetes Research Foundation United States of America"
    ]
}